Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies
By Adriano Marchese
Zentalis Pharmaceuticals shares were down in premarket trading after the company said partial clinical holds were placed on three of its cancer treatment studies.
Ahead of the morning bell, shares were trading nearly 27% lower at $6.15.
The clinical-stage biopharmaceutical said the U.S. Food and Drug administration has placed a partial clinical hold on studies for its drug, Azenosertib.
The company said it is working with the regulator to resolve the partial clinical hold as quickly as possible.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 18, 2024 07:59 ET (11:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks